ArticleCureus2025
Myofibroblastic Proliferation as a Secondary Malignancy From Radioactive Iodine Treatment for Thyroid Carcinoma: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid carcinoma is an important health issue having significant morbidity and mortality. Management includes thyroidectomy followed by radioactive iodine ablation to kill any remaining tumor cells. However, the use of radioactive iodine ablation (RAI) is not without risks; one such risk is the development of secondary cancers, especially in patients undergoing radioactive iodine ablation at a younger age. We present a case of thyroid carcinoma where the patient was treated with radioactive iodine ablation over 20 years ago. The patient was recently found to have a neck mass, which was investigated with imaging and biopsied. Pathological findings were consistent with myofibroblastic proliferation, which is a benign abnormal growth of myofibroblasts but has small potential for malignant transformation. Management generally involves surgical excision, and other treatments like steroids, non-steroidal anti-inflammatory drugs, and radiation therapy can be used in select cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.